-
公开(公告)号：US11186636B2
公开(公告)日：2021-11-30
申请号：US16500378
申请日：2018-04-20
Applicant: AMGEN INC.
Inventor： Ian Foltz , Shilpa Sambashivan , Irwin Chen , Susie Miki Harris , Dora Toledo Warshaviak , Ian Driver , Daniel Lu
Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.
-
公开(公告)号：US20210054069A1
公开(公告)日：2021-02-25
申请号：US16500378
申请日：2018-04-20
Applicant: AMGEN INC.
Inventor： Ian Foltz , Shilpa Sambashivan , Irwin Chen , Susie Miki Harris , Dora Toledo Warshaviak , Ian Driver , Daniel Lu
Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.
-
Search Results
2
records
(took 0.009 seconds)
